ROCKVILLE, Md. and SUZHOU, China, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that it has received clearance by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) to conduct GLORA-4 study (NCT06641414), a global registrational Phase III study of lisaftoclax (APG-2575), a proprietary Bcl-2 inhibitor, in combination with azacitidine (AZA), for the treatment of patients with newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS).
The stem cell banking market is booming due to advancements in tech and regenerative medicine, rising healthcare spend, private investments, and ethical shifts favoring adult stem cells. Key opportunities lie in personalized healthcare, clinical trials, and expanding access globally, with North America leading market growth.
The stem cell banking market is booming due to advancements in tech and regenerative medicine, rising healthcare spend, private investments, and ethical shifts favoring adult stem cells. Key opportunities lie in personalized healthcare, clinical trials, and expanding access globally, with North America leading market growth.
The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...
The outlook for the neuroblastoma treatment market is optimistic, fueled by progress in targeted therapies and immunotherapies. GD2-targeted immunotherapy is increasingly being incorporated into...
Call Scheduled for August 14, 2025, at 8:30 AM Eastern Time
NEW YORK, Aug. 8, 2025 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (OTCQB: BCLI), a leading...
MELVILLE, N.Y., Aug. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its second quarter 2025 financial results after market close on Tuesday, August 12, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update.
"Market Analysis Highlights Growth Potential, Emerging Technologies, ESG Trends, and Strategic Insights in the Cell Line and Membrane Sector"
BOSTON, Aug. 5, 2025 /PRNewswire/ --...
The cell culture market is anticipated to expand at a rapid pace owing to growing innovations in biotechnologies, and biopharmaceuticals on the back of...
Clinical Stage Biotechnology Company Uses Patient Immune System to "Seek and Destroy" Cancer and Metastasis
SAN DIEGO, Aug. 1, 2025 /PRNewswire/ -- Res Nova Biologics,...
Burlingame, CA, July 15, 2025 (GLOBE NEWSWIRE) -- The global Vitrification Market is estimated to be valued at USD 10.82 Bn in 2025 and is expected to reach USD 31.15 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 16.3% from 2025 to 2032. The vitrification market is witnessing growing demand due to its expanding applications in biobanking, assisted reproductive technologies, and cryopreservation of oocytes, embryos, and stem cells. This technique offers faster cooling rates and higher cell survival compared to conventional freezing, making it increasingly preferred in fertility clinics and research institutions. Market growth is also driven by advancements in cryoprotectant solutions and rising awareness of fertility preservation. Opportunities lie in emerging markets, technological innovations, and collaborations between biotech firms and healthcare providers to improve storage protocols and expand access to vitrification services.